Piper Sandler Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price

Sarepta Therapeutics (NASDAQ:SRPT) had its target price decreased by analysts at Piper Sandler from $23.00 to $20.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Piper Sandler’s price objective indicates a potential downside of 1.46% from the company’s previous close.

A number of other research firms also recently weighed in on SRPT. Wedbush lifted their price objective on Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 26th. Wall Street Zen raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Citigroup raised their target price on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research report on Thursday, March 26th. Mizuho boosted their price target on Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Finally, HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Nine equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and seven have issued a Sell rating to the stock. According to MarketBeat.com, Sarepta Therapeutics presently has an average rating of “Hold” and a consensus target price of $25.09.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock traded up $0.09 on Thursday, hitting $20.30. The company’s stock had a trading volume of 1,053,509 shares, compared to its average volume of 3,079,724. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $25.32. The firm has a market cap of $2.14 billion, a P/E ratio of -21.17, a price-to-earnings-growth ratio of 0.21 and a beta of 0.21. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. The company has a fifty day moving average price of $17.80 and a 200-day moving average price of $19.29.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. The company had revenue of $730.80 million during the quarter, compared to the consensus estimate of $474.15 million. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm earned ($3.42) EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post 3.95 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new position in shares of Sarepta Therapeutics in the fourth quarter valued at about $25,000. iSAM Funds UK Ltd acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at about $25,000. Ancora Advisors LLC increased its position in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares in the last quarter. Allworth Financial LP increased its position in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 1,256 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.